Abbott Laboratories (ABT)
NYSE: ABT
· Real-Time Price · USD
129.32
-0.08 (-0.06%)
At close: Aug 14, 2025, 3:59 PM
129.92
0.46%
Pre-market: Aug 15, 2025, 08:50 AM EDT
Abbott Laboratories Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostic Products Revenue | 9.34B | 9.99B | 16.58B | 15.64B | 10.8B | 7.71B | 7.5B | 5.62B | 4.81B | 4.65B | 4.72B | 4.54B | 4.29B | 4.13B |
| Diagnostic Products Revenue Growth | -6.48% | -39.77% | +6.01% | +44.78% | +40.09% | +2.91% | +33.46% | +16.68% | +3.59% | -1.59% | +3.87% | +5.89% | +4.02% | n/a |
| Established Pharmaceutical Products Revenue | 5.19B | 5.07B | 4.91B | 4.72B | 4.3B | 4.49B | 4.42B | 4.29B | 3.86B | 3.72B | 3.12B | 4.97B | 5.12B | 5.41B |
| Established Pharmaceutical Products Revenue Growth | +2.53% | +3.14% | +4.11% | +9.64% | -4.08% | +1.45% | +3.15% | +11.09% | +3.74% | +19.31% | -37.31% | -2.87% | -5.39% | n/a |
| Medical Devices Revenue | 18.99B | 16.89B | 14.69B | 14.37B | 11.79B | 12.24B | 7.23B | 6.92B | 6.9B | 6.97B | 6.95B | 6.74B | 6.47B | 6.01B |
| Medical Devices Revenue Growth | +12.43% | +14.98% | +2.23% | +21.89% | -3.69% | +69.30% | +4.39% | +0.38% | -1.09% | +0.32% | +3.16% | +4.16% | +7.74% | n/a |
| Nutritional Products Revenue | 8.41B | 8.15B | 7.46B | 8.29B | 7.65B | 7.41B | 9.44B | 8.91B | n/a | n/a | n/a | n/a | n/a | n/a |
| Nutritional Products Revenue Growth | +3.18% | +9.32% | -10.07% | +8.46% | +3.21% | -21.49% | +5.90% | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Us Revenue | 14.85B | 14.08B | 14.84B | 15.52B | 1.14B | 1.07B | 1B | 841M | 766M | 784M | 707M | 1.08B | 1.74B | 22.84B | 19.97B |
| Non-Us Revenue Growth | +5.41% | -5.10% | -4.34% | +1260.96% | +6.74% | +6.27% | +19.50% | +9.79% | -2.30% | +10.89% | -34.72% | -37.76% | -92.38% | +14.34% | n/a |
| C [N] Revenue | 2.11B | 2.25B | 2.13B | 2.39B | 1.97B | 2.35B | 2.31B | 2.15B | 1.73B | 1.8B | 1.32B | 1.07B | 933M | 16.01B | 15.19B |
| C [N] Revenue Growth | -6.21% | +5.63% | -10.83% | +21.73% | -16.24% | +1.51% | +7.69% | +24.19% | -3.79% | +35.96% | +23.46% | +14.68% | -94.17% | +5.40% | n/a |
| D [E] Revenue | 2.54B | 2.35B | 2.34B | 2.57B | 2.11B | 1.75B | 1.62B | 1.37B | 1.04B | 1B | 978M | 922M | 2.44B | n/a | n/a |
| D [E] Revenue Growth | +8.27% | +0.21% | -9.02% | +22.01% | +20.39% | +8.15% | +18.52% | +30.84% | +3.98% | +2.66% | +6.07% | -62.23% | n/a | n/a | n/a |
| I [N] Revenue | 1.82B | 1.75B | 1.65B | 1.56B | 1.32B | 1.4B | 1.33B | 1.24B | 1.11B | 1.05B | 1.01B | 1.44B | 1.88B | n/a | n/a |
| I [N] Revenue Growth | +3.83% | +6.12% | +5.64% | +17.99% | -5.30% | +4.80% | +7.76% | +11.04% | +5.79% | +4.36% | -30.03% | -23.42% | n/a | n/a | n/a |
| J [P] Revenue | 1.44B | 1.51B | 1.93B | 1.7B | 1.39B | 1.44B | 1.33B | 1.25B | 924M | 895M | 968M | 960M | 10.55B | n/a | n/a |
| J [P] Revenue Growth | -4.76% | -21.69% | +13.98% | +22.29% | -3.41% | +8.22% | +5.66% | +35.82% | +3.24% | -7.54% | +0.83% | -90.90% | n/a | n/a | n/a |
| N [L] Revenue | 1.12B | 1.07B | 1.34B | 1.31B | 1.08B | 975M | 930M | 929M | 830M | 855M | 788M | 5.28B | 16.78B | n/a | n/a |
| N [L] Revenue Growth | +4.66% | -19.61% | +1.75% | +21.13% | +11.18% | +4.84% | +0.11% | +11.93% | -2.92% | +8.50% | -85.08% | -68.52% | n/a | n/a | n/a |
| C [H] Revenue | 1.75B | 1.64B | 18.14B | 16.64B | 12.58B | 11.53B | 11.21B | 5.74B | 4.99B | 4.88B | 5.17B | 792M | n/a | n/a | n/a |
| C [H] Revenue Growth | +6.65% | -90.97% | +9.01% | +32.29% | +9.07% | +2.84% | +95.35% | +15.07% | +2.23% | -5.54% | +552.27% | n/a | n/a | n/a | n/a |
| United States Revenue | 16.32B | 15.45B | n/a | n/a | 13.02B | 11.4B | 10.84B | 9.67B | 6.49B | 6.27B | 6.12B | 6.27B | n/a | n/a | n/a |
| United States Revenue Growth | +5.64% | n/a | n/a | n/a | +14.25% | +5.16% | +12.05% | +49.14% | +3.44% | +2.40% | -2.33% | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 3.09B | 3.05B | 2.88B | 2.9B | 2.92B | 2.95B | 2.7B | 2.69B | 2.72B | 2.75B | 2.84B | 2.73B | 2.76B | 2.79B | 3B | 2.77B | 2.72B | 2.78B | 2.58B | 2.3B | 2.27B | 2.55B | 2.4B | 2.41B | 2.43B | 2.46B | 2.35B | 2.36B | 2.46B | 2.53B | 2.43B | 2.08B | 2.15B | 2.3B | 1.6B | 1.62B | 1.74B | 1.7B | 1.66B | 1.67B | 1.73B | 1.74B |
| Selling, General, and Administrative Revenue Growth | +1.31% | +6.01% | -0.52% | -0.92% | -1.08% | +9.25% | +0.33% | -1.06% | -0.98% | -3.10% | +4.15% | -1.12% | -1.08% | -7.22% | +8.60% | +1.58% | -2.16% | +8.08% | +12.15% | +0.92% | -10.71% | +6.03% | -0.46% | -0.78% | -1.14% | +4.90% | -0.64% | -3.91% | -2.77% | +4.08% | +16.73% | -3.26% | -6.48% | +43.33% | -0.87% | -6.85% | +2.30% | +2.60% | -0.66% | -3.53% | -0.58% | n/a |
| Research and Development Revenue | 732M | 703M | 728M | 713M | 697M | 683M | 690M | 661M | 710M | 654M | 691M | 780M | 684M | 697M | 758M | 672M | 654M | 654M | 698M | 580M | 564M | 576M | 575M | 594M | 577M | 670M | 561M | 573M | 573M | 581M | 618M | 493M | 520M | 541M | 338M | 336M | 348M | 379M | 369M | 378M | 345M | 313M |
| Research and Development Revenue Growth | +4.13% | -3.43% | +2.10% | +2.30% | +2.05% | -1.01% | +4.39% | -6.90% | +8.56% | -5.35% | -11.41% | +14.04% | -1.87% | -8.05% | +12.80% | +2.75% | 0.00% | -6.30% | +20.34% | +2.84% | -2.08% | +0.17% | -3.20% | +2.95% | -13.88% | +19.43% | -2.09% | 0.00% | -1.38% | -5.99% | +25.35% | -5.19% | -3.88% | +60.06% | +0.60% | -3.45% | -8.18% | +2.71% | -2.38% | +9.57% | +10.22% | n/a |